Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
Phase 1/2 Withdrawn
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
Phase 1/2 Withdrawn
CAR19T2
Phase 1/2 Withdrawn
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase 1/2 Withdrawn
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Phase 1/2 Withdrawn
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
Phase 1/2 Withdrawn
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Phase 1/2 Withdrawn
CD19-targeting CAR T Cells for B Cell Lymphoma
Phase 1/2 Withdrawn
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
Phase 1/2 Withdrawn
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 1/2 Withdrawn
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase 1/2 Withdrawn
Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients
Phase 1/2 Withdrawn
ABC-102
Phase 1/2 Withdrawn
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Phase 1/2 Withdrawn
Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.
Phase 1/2 Withdrawn
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
Phase 1/2 Withdrawn
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
Phase 1/2 Withdrawn
Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma
Phase 1/2 Withdrawn
Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma
Phase 1/2 Withdrawn
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Phase 1/2 Withdrawn
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
Phase 1/2 Withdrawn